{
    "clinical_study": {
        "@rank": "56935", 
        "acronym": "DUE", 
        "arm_group": [
            {
                "arm_group_label": "Fellow arm", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients in this arm will receive the ID fellow-based antibiotic pre-authorization intervention."
            }, 
            {
                "arm_group_label": "Pharmacist arm", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients in this arm will receive the pharmacist-based antibiotic pre-authorization intervention."
            }
        ], 
        "brief_summary": {
            "textblock": "We will conduct a cluster randomized controlled trial to compare two antibiotic\n      pre-authorization strategies (Fellow-based vs. Pharmacist-based). We believe that amount and\n      duration of antibiotic consumption would be lower in the pharmacist group while the clinical\n      outcome would be equivalent between two groups."
        }, 
        "brief_title": "A Comparative Study of ID Fellow-based VS. Pharmacist-based Antibiotic Pre-authorization", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "All Hospitalzied Patients", 
            "No Specific Conditions Requires"
        ], 
        "detailed_description": {
            "textblock": "Study design: A cluster randomized controlled trial Settings: 6 general medical wards at\n      Siriraj Hospital, Bangkok, Thailand"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Hospitalized patients\n\n          -  Received at least one dose of controlled antibiotics (Piperacillin/Tazobactam,\n             Imipenem/Cilastatin, Meropenem or Doripenem)\n\n          -  Each patient may be enrolled more than once, if he/she receives the controlled\n             antibiotic for a new episode of infection (at least 48 hour apart)\n\n        Exclusion Criteria:\n\n          -  Died prior to receive the controlled antibiotic"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": {
            "#text": "984", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01797133", 
            "org_study_id": "647/2555(EC1)"
        }, 
        "intervention": [
            {
                "arm_group_label": "Fellow arm", 
                "description": "All prescriptions of controlled antibiotics (Piperacillin/Tazobactam, Imipenem/Cilastatin, Meropenem and Doripenem) can be freely prescribed for the first 72 hours. After that, the prescription requires approval. Antibiotic preauthorization program will be operated by ID-fellows, under the supervision of ID staffs.", 
                "intervention_name": "ID fellow-based antibiotic pre-authorization", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Pharmacist arm", 
                "description": "All prescriptions of controlled antibiotics (Piperacillin/Tazobactam, Imipenem/Cilastatin, Meropenem and Doripenem) can be freely prescribed for the first 72 hours. After that, the prescription requires approval. Antibiotic preauthorization program will be operated by general pharmacists, under the supervision of ID staffs.", 
                "intervention_name": "Pharmacist-based antibiotic pre-authorization", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Bacterial Agents", 
                "Antibiotics, Antitubercular"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 20, 2013", 
        "location": {
            "contact": {
                "email": "pinyo.rat@mahidol.ac.th", 
                "last_name": "Pinyo Rattanaumpawan, MD, MSCE", 
                "phone": "6624197783"
            }, 
            "facility": {
                "address": {
                    "city": "Bangkok", 
                    "country": "Thailand", 
                    "zip": "10700"
                }, 
                "name": "Siriraj Hospital"
            }, 
            "investigator": {
                "last_name": "Pinyo Rattanaumpawan, MD, MSCE", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Comparative Study of ID Fellow-based Pre-authorization VS. Pharmacist-based Pre-authorization in Reducing Antibiotic Consumptions and Hospital Expenditures", 
        "other_outcome": {
            "description": "Clinial response (cure, improved, not improved, dead and refer) at the end of therapy and at discharge", 
            "measure": "Clinical response", 
            "safety_issue": "Yes", 
            "time_frame": "at the end of therapy and at discharge (an average duration of antibiotic therapy is 2 weeks, an average length of stay is 3 weeks)"
        }, 
        "overall_official": {
            "affiliation": "Mahidol University", 
            "last_name": "Pinyo Rattanaumpawan, MD, MSCE", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Thailand: Ethical Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "DDD of antibiotic use for that given infection (all antibiotics and controlled antibiotics)", 
            "measure": "Defined Daily Dose (DDD) of antibiotics", 
            "safety_issue": "No", 
            "time_frame": "Participants will be followed for the total duration of antibiotic therapy for that given infection, an expected average of 2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01797133"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Siriraj Hospital", 
            "investigator_full_name": "Pinyo Rattanaumpawan", 
            "investigator_title": "Asssitant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Total duration of antibiotic use for that given infection (all antibiotics and controlled antibiotics)", 
            "measure": "Total duration of antibiotic use", 
            "safety_issue": "No", 
            "time_frame": "Participants will be followed for the total duration of antibiotic therapy for that given infection, an expected average of 2 weeks"
        }, 
        "source": "Siriraj Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Mahidol University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Siriraj Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}